Unique Cysteine-Directed Covalent Inhibition of PRMT1 Suppresses Breast Tumorigenesis.

Authors

Min Shao, Ruining Li, Jinglei Hu, Wenjie Xi, Raghupathi Mutyala, Lulu Guan, Chaoqun Huang, Renhong Sun, Xiaobao Yang, Bo Jin, Bo Zhao, Erjun Hao, Zhimin Zhang, Lin Li, Xufen Yu, Mingyan Zhu, Yudao Shen

Published in

Journal of medicinal chemistry. Jun 17, 2026. Epub Jun 17, 2026.

Abstract

Dysregulation of PRMT1, a key epigenetic enzyme, is strongly implicated in breast cancer pathogenesis. However, developing selective PRMT1 inhibitors has been challenging due to the high conservation of the catalytic domain across PRMT family members. We herein report 17zh (MS3-123), the first small-molecule, nanomolar covalent inhibitor targeting the unique Cys119 within the SAM-binding pocket of PRMT1 (IC₅₀ = 11.4 nM) with over 17-96-fold selectivity against other type I PRMTs subfamily and >439-fold selectivity against type II PRMT5. 17zh selectively engages Cys119, inhibiting PRMT1 activity at both enzymatic and cellular levels. Functionally, 17zh suppressed breast cancer cell proliferation, migration, invasion, induced cell cycle arrest and apoptosis, and impaired tumor growth in vivo in the MDA-MB-231-xenograft model. Our findings establish 17zh as both a valuable chemical probe for PRMT1 research and a promising lead candidate for breast cancer treatment, highlighting the potential of covalent targeting for selective epigenetic drug discovery.

PMID:
42309962
Bibliographic data and abstract were imported from PubMed on 18 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.